Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Kim

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Small (Weinheim an Der Bergstrasse, Germany)|July 19, 2012
Microarray with micro- and nano-topographies enables identification of the optimal topography for directing the differentiation of primary murine neural progenitor cellsAung Aung Kywe Moe, Mona Suryana, Guillaume Marcy, et al.
Journal of Clinical Medicine|December 24, 2021
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional StudyGili Kenet, Yeu-Chin Chen, Gillian Lowe, et al.
The New England Journal of Medicine|October 2, 2004
Pure red-cell aplasia and epoetin therapyCharles L Bennett, Stefano Luminari, Allen R Nissenson, et al.
The New England Journal of Medicine|March 16, 2022
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AMargareth C Ozelo, Johnny Mahlangu, K John Pasi, et al.
Journal of the American College of Cardiology|September 18, 2007
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR ProjectCharles L Bennett, Benjamin Kim, Anaadriana Zakarija, et al.
Blood|August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.
Research Square|October 27, 2023
A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-ATom Howard, Marcio Almieda, Vincent Diego, et al.
Genes and Immunity|April 22, 2025
A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia AMarcio A Almeida, Vincent P Diego, Kevin R Viel, et al.
Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.
Genes and Immunity|September 25, 2025
Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia AMarcio A Almeida, Vincent P Diego, Kevin R Viel, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Small (Weinheim an Der Bergstrasse, Germany)|July 19, 2012
Microarray with micro- and nano-topographies enables identification of the optimal topography for directing the differentiation of primary murine neural progenitor cellsAung Aung Kywe Moe, Mona Suryana, Guillaume Marcy, et al.
Journal of Clinical Medicine|December 24, 2021
Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional StudyGili Kenet, Yeu-Chin Chen, Gillian Lowe, et al.
The New England Journal of Medicine|October 2, 2004
Pure red-cell aplasia and epoetin therapyCharles L Bennett, Stefano Luminari, Allen R Nissenson, et al.
The New England Journal of Medicine|March 16, 2022
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia AMargareth C Ozelo, Johnny Mahlangu, K John Pasi, et al.
Journal of the American College of Cardiology|September 18, 2007
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR ProjectCharles L Bennett, Benjamin Kim, Anaadriana Zakarija, et al.
Blood|August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.
Research Square|October 27, 2023
A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-ATom Howard, Marcio Almieda, Vincent Diego, et al.
Genes and Immunity|April 22, 2025
A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia AMarcio A Almeida, Vincent P Diego, Kevin R Viel, et al.
Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.
Genes and Immunity|September 25, 2025
Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia AMarcio A Almeida, Vincent P Diego, Kevin R Viel, et al.
Pageof 9